Treatment of orbital myositis with adalimumab (Humira).
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 15996084.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Adalimumab is a fully humanized IgG1 monoclonal antibody to tumor necrosis factor-a. We describe 2 patients (17 and 13 years of age) with refractory, steroid-dependent, recurrent nonspecific orbital myositis not controlled with standard immunosuppressive medications. Both improved with adalimumab treatment, allowing reduction in corticosteroid dosage without disease flare.
Medical subject headings
- Antibodies, Monoclonal
- Orbital Pseudotumor
- Tumor Necrosis Factor-alpha